Pages that link to "Q35469575"

The following pages link to Comparative efficacy of switching to natalizumab in active multiple sclerosis (Q35469575):

Displaying 26 items.

• Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations (Q26752859) (← links)
• Observational data: Understanding the real MS world (Q30249781) (← links)
• Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients (Q33764067) (← links)
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. (Q36202727) (← links)
• Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis (Q36484448) (← links)
• Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. (Q36789883) (← links)
• Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research (Q36826621) (← links)
• Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany (Q37626336) (← links)
• Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet? (Q38777286) (← links)
• Treatment decisions in multiple sclerosis - insights from real-world observational studies. (Q39022643) (← links)
• Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study (Q39675286) (← links)
• Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study (Q39685700) (← links)
• Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies (Q39732691) (← links)
• Predictors of long-term disability accrual in relapse-onset multiple sclerosis (Q39795220) (← links)
• The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis (Q40710140) (← links)
• The importance of collecting structured clinical information on multiple sclerosis (Q42747344) (← links)
• Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. (Q48204088) (← links)
• Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry (Q48224174) (← links)
• Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. (Q48910491) (← links)
• Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis (Q48967402) (← links)
• Long-term registries: Answering tough questions with big data? (Q49353031) (← links)
• ["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy]. (Q53288359) (← links)
• Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing (Q57162830) (← links)
• Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy (Q90264381) (← links)
• Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review (Q91705602) (← links)
• Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy (Q93111731) (← links)